Investors & Media

Press Releases

Date Title View
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on June 1, 2017 , the Compensation Committee of Sage's Board of Directors
View HTML
Toggle Summary Sage Therapeutics Receives Fast Track Designation for SAGE-217 for the Treatment of Major Depressive Disorder
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track
View HTML
Toggle Summary Sage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update
Phase 3 STATUS Trial of brexanolone in SRSE nearing completion of enrollment - expects top-line results in Q3 2017 Advancing SAGE-217 into Part B open-label Phase 2 trial in Parkinson's disease based on initial activity signal First patient dosed in placebo-controlled Phase 2 clinical trial of
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on May 1, 2017 , the Compensation Committee of Sage's Board of Directors
View HTML
Toggle Summary Sage Therapeutics Announces Initiation of Phase 1 Development and First Dosing of SAGE-718
Lead compound from novel NMDA modulator product development platform Top-line results from single ascending dose trial expected in 2H 2017 CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat
View HTML
Toggle Summary Sage Therapeutics to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Tuesday, May
View HTML
Toggle Summary Sage Therapeutics Appoints Michael Cloonan as Chief Business Officer and Expands Executive Team
Key additions and promotions to team in commercial, development and regulatory roles CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today
View HTML
Toggle Summary Sage Therapeutics to Present at American Academy of Neurology 2017 Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations for brexanolone (SAGE-547) and SAGE-217 at the American
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on April 3, 2017 , the Compensation Committee of Sage's Board of Directors
View HTML
Toggle Summary Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Sage Therapeutics  (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on March 1, 2017 , the Compensation Committee of Sage's Board of Directors
View HTML